About the ProVent Study
The life-saving effects of immunotherapy treatment with sipuleucel-T have been proven in some men with advanced prostate cancer (also referred to as metastatic castrate-resistant prostate cancer or mCRPC), and research suggests that this cutting-edge therapy may also benefit men with lower risk prostate cancer who are on active surveillance (AS).
Nearly 175,000 men are diagnosed with prostate cancer every year.[i] Of these, about 30 to 40% with a lower risk of prostate cancer will opt for AS[ii]. A new study will evaluate the effectiveness of sipuleucel-T in reducing disease progression in men who are candidates for AS and looking for a proactive alternative to surgery or radiation.
AS has grown in popularity as a treatment option for men with lower risk prostate cancer and includes regular prostate-specific antigen (PSA) testing and tumor biopsies (every 1-2 years) to ensure the cancer is not growing or spreading. Choosing AS may allow some men to delay – or even avoid – surgery and radiation, which often result in life-altering side effects.[iii]
ProVent Study Details (NCT03686683)